Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | RGS4 | P49798 | 2/20 | 0.38 |
| ▸ | RGS8 | P57771 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064255 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL5061447 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL5134174 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL5064737 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL102314 | 0.84 | EHMT2 (0.49) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL4187223 | 0.84 | EHMT2 (0.49) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL4597179 | 0.84 | EHMT2 (0.49) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL5066408 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL8104393 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL8104388 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727526-A2 | PIPERAZINE UREA DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | Schering Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005079769-A2 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | WO | disclosed |
| US-20040058932-A1 | Novel piperazine derivatives | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6649611-B2 | Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1268455-A2 | PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072728-A9 | NOVEL PIPERAZINE DERIVATIVES | PFIZER PROD INC (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020107255-A1 | Novel piperazine derivatives | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2001072728-A2 | NOVEL PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058932-A1 | Novel piperazine derivatives | IL5, IL17A, CCR2 | ALDH1A1 401/4885KMT2A 2957/4885MEN1 4741/4885 |
| US-20020107255-A1 | Novel piperazine derivatives | IL5, IL17A, CCR2 | ALDH1A1 401/4885KMT2A 2957/4885MEN1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.